Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or original empirical data.
PubMed 40980310 · doi:10.4239/wjd.v16.i9.109123
What was done
This narrative review synthesized literature on incretin-based weight loss medications (GLP-1, GLP-1/GIP dual, and GLP-1/GIP/glucagon triple receptor agonists such as semaglutide, tirzepatide, and retatrutide) and their effects on body composition. The authors evaluated the risks of lean mass loss and explored potential combinations with emerging anti-obesity agents and myokine-related pathways to preserve muscle tissue.
What was found
The abstract reports no primary experimental or clinical trial data. It notes that achieving 5% to 10% weight loss with incretin-based therapies results in lean mass and muscle loss alongside fat reduction, potentially increasing the risk of sarcopenia and long-term weight regain. It also highlights that over 600 myokines linked to muscle contraction have been identified in human myocytes as candidate targets for muscle preservation.
Why it matters
As incretin-based drugs become widely adopted, lean mass loss is an important side effect that may impair metabolic health and physical function. This article outlines the conceptual need to shift treatment goals from gross weight loss to body-composition-preserving strategies.
Limits
This is a non-systematic narrative review with no primary data, quantitative synthesis, or direct clinical trial results assessing specific muscle-preservation strategies.
Cited by
- contradicts Retatrutide preserves muscle mass during weight loss.